Is lipoprotein(a) an LDL-like particle with apolipoprotein B that raises ASCVD risk independently of triglycerides and glucose?

Lipoprotein(a), or Lp(a), is a highly atherogenic, genetically determined lipoprotein particle. Understanding its unique structure and independent risk profile is critical for accurate cardiovascular risk assessment.

Molecular structure and assembly

• Lp(a) consists of a low-density lipoprotein (LDL)-like core containing a neutral lipid center and a single molecule of apolipoprotein B-100 (apoB-100).
• The defining characteristic of Lp(a) is the covalent attachment of a highly glycosylated glycoprotein, apolipoprotein(a) [apo(a)], to the apoB-100 molecule.
• This assembly occurs via a stable, two-step process: initial noncovalent interactions at specific lysine residues are followed by the formation of a single intermolecular disulfide bond between specific cysteine residues on both proteins.

Independent cardiovascular risk

• Large-scale prospective cohorts and Mendelian randomization studies establish that elevated Lp(a) levels causally increase the risk of atherosclerotic cardiovascular disease (ASCVD).
• This risk is highly independent of triglycerides and glucose. Adjusting for these metabolic markers or composite indices like the triglyceride-glucose (TyG) index does not attenuate Lp(a)'s predictive power, demonstrating that Lp(a) operates via a distinct, additive risk pathway.
• Genetically, higher Lp(a) levels are paradoxically associated with a decreased risk of Type 2 diabetes. However, this inverse metabolic relationship does not confound or mitigate the direct, potent atherogenic impact of elevated Lp(a) on the vasculature.

Bottom line

• Lipoprotein(a) is a distinct, LDL-like particle containing apolipoprotein B-100 that causally drives cardiovascular risk through pathways entirely independent of glucose, triglycerides, and traditional metabolic risk markers.